tions and counseled stop treatment and seek attention if signs or symptoms such as jaundice abdominal pain severe nausea or fever develop Hepatotoxicity and clinical hepatitis are serious adverse events associated with drugs that are currently used for the treatment of tuberculosis (Ta-ble 2) Unfortunately there is a paucity of data on the role of visits to monitor adverse events The role of the tests and the frequency of visits should be defined on the basis of the clinical indications and social profile of the person being treated as well as the capacity of clinical services Initial screening with liver-function tests and regular measurement of liver function afterward could facilitate clinical management Persons with underlying liver disease those receiving antiretroviral therapy won who are pregnant or post partum alcohol abusers or person who are receiving long-term treatment with potentially hepatotoxic medications should be given priority for regular liver-enzyme monitoring